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Abstract A eDNA encoding a variant form of the A3 adenosine 
(Ado) receptor was isolated from rat by reverse transcription of 
brain mRNA followed by PCR. The full-length receptor (A3i) 
cDNA encodes 337 amino acids and shares complete sequence 
identity with the rat A3 Ado receptor, except for the presence of 
a seventeen amino acid insert located in the second intraeellular 
domain. In contrast o the rat A3 receptor, stable expression of 
A31 in CHO cells resulted in poor coupling to Gi proteins. 
Analysis of receptor transcripts by RT-PCR suggests that the A3 
Ado receptor mRNAs are products of alternative splicing. 
Sequence analysis of A3 genomic DNA Identified a 1.7 kb 
intron that is likely alternatively spliced to produce the A3 and 
A31 receptors. 
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1. Introduction 
Ado receptors mediate a variety of physiological functions 
in the cardiovascular nd central nervous system and are im- 
portant regulators of allergic and immunologic responses 
[1,2]. Ado receptors function in part through heterotrimeric 
G-proteins and display subtype heterogeneity, with four 
known receptor subtypes, the A I [3], A2a [4], A2b [5] and 
A3 Ado receptors [6]. The recently identified A3 Ado recep- 
tor, which was originally cloned from rat testis and brain 
cDNA libraries [7,8], exhibited about 50-60% homology 
with rat A I and A2 receptors. This new receptor showed 
ligand binding characteristics that distinguished it from A1 
or A2 receptors, with relatively high affinity for I.APNEA, 
I.ABA, and IB-MECA [8,9]. However, the rat receptor dis- 
played low binding affinity for the antagonists DPCPX and 
XAC and had surprisingly low homology to both the sheep 
(72%) [10] and human receptors (72%) [I 1]. In contrast, the 
A I and A2 Ado receptors are highly conserved between spe- 
cies [1]. The tissue distribution of the rat A3 Ado receptor 
appeared to be distinct from that of the sheep and human 
receptors, although previous studies in the rat relied solely 
on RT-PCR to detect specific RNA transcripts [6,8,10]. 
We have now cloned the rat A3 Ado receptor and identified 
several nucleotides in the sequence that differ from previously 
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published reports. Northern blot analysis revealed evidence of 
alternative splicing in the rat as well as a restricted tissue 
distribution compared to other species. Furthermore, an alter- 
natively spliced variant of the A3 Ado receptor containing an 
insert in the second cytoplasmic domain was identified and 
confirmed by characterization of the corresponding enomic, 
region. This variant was named A3i to denote the presence of' 
the in-frame insert. 
2. Material and methods 
2. i. Reverse transcription PCR and sequencing 
mRNA was purified from rat brain and spleen using oligo-dT (Qia- 
gen, Chattsworth, CA). Single-stranded cDNAs for brain and spleen 
and rat genomic DNA were obtained from Clontech (Palo Alto, CA). 
Reverse transcribed eDNA was subjected to PCR amplification with 
the following primers: A-(5'-CACATCCTGCTGAAGAAGCAA- 
CAG); B-(5'-ACTCTCGAGCTGGCTCTTTATCTGTCATGG); C- 
(5'-GAAAGCCAACAATACCACGACGAG); D-(5'-CAAA- 
GAATCCGAGGTCTGACAGAG); E-(5'-GTCCAGATGCACTTC- 
TATGCCTGC); F-(5'-GACCATGTAATCCAAGCCGACCAC); I. 
(GTTGTGAACTrACCGTTITCCTCC). PCR (26-35 cycles) con- 
sisted of denaturing at 94°C for 20 s, hybridization at 60°C for 25 s 
and extension at 72°C for 30 s using a Perkin Elmer 480 instrument 
and reagents (Perkin Elmer, Foster City, CA). PCR products were 
concentrated on micro spin filters (Amicon, Beverly, MA) and re. 
solved on 0.7-1.1% agarose gels. 
eDNA bands of interest were purified, subjected to restriction di- 
gestion and cloned into pBluescript (Stratagene, San Diego, CA) using 
established protocols [12] and subjected to sequence analysis (both 
strands for the coding region) by the dideoxy termination method 
using Sequenase (USB, Cleveland, OH). The 2.3 kb fragment span- 
ning the A3 intron region was cloned into pCRII (Invitrogen, San 
Diego, CA). 
2.2. Northern blot hybridization 
A rat multiple tissue mRNA blot (Clontech, Palo Alto, CA) was 
probed with the full length A3i probe, an oligo spanning the A3i 
insert region and a human ~-actin eDNA, as previously described 
[6]. Autoradiography was carried out using Reflection X-Ray film 
and intensifying screens (Dupont, Boston, MA). 
2.3. DNA transfection and cAMP measurements 
The 1.1 kb A3i eDNA and a I kb rat A3 eDNA were cloned as 
HindIlI.Xhol fragments into the expression vector pcDNA3 (Invitro- 
gen, San Diego, CA). CHO-KI cells were stably transfected using 
lipofectamine reagent (Gibco, Gaithersburg, MD). Neomycin-resist- 
ant colonies were isolated following selection in 800 mg/ml (3418 
(Gibeo, Gaithersburg, MD). To check the expression levels of trans- 
fectants, mRNA was purified from several clones and subjected to 
Northern blot analysis using the A3 eDNA as probe. 
For cAMP assays, cells were grown to ,,- 90% confluence in 24-well 
tissue culture cluster plates and washed in phosphate-buffered saline. 
Cells were subsequently treated with adenosine deaminase (2 U/ml) 
for 10 min in RPMI medium (no FCS) followed by the addition of 
forskolin and I-ABA for an additional 10 rain. Cells were washed with 
PBS and assays were terminated by addition of 70% ethanol and 
subsequent incubation on ice for 1 h. Cells were scraped from the 
wells and supernatants cleared of cell debris by brief centrifugation. 
Supernatants were dried under a stream of nitrogen and cAMP was 
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Fig. !. (A) Schematic of the rat A3i eDNA. Primers corresponding to their positions on the eDNA are indicated by arrows and the corre- 
sponding PCR products and their sizes are shown below (M = size markers). (B) Primers A and B; Digestion products of rat A3 and A3i Ado 
receptors esolved on an agarose gel. (C) Primers I + D; Amplification of the 614 bp product obtained from splenic mRNA, in the presence 
and absence of reverse transcriptase (+RT or -RT, respectively). The lack of signal without RT rules out contamination asthe source of A3i 
signal. (D) Primers A + B, C + F, I + D; PCR products from eDNA pools of brain (Br) and spleen (S) resolved on agarose gel. 
quantified using the Titerzyme cAMP EIA kit (Perseptive Diagnostics, 
Inc., Cambridge, MA), in accordance with the manufacturer's in truc- 
tions. 
3. Rmu~ts 
RT-PCR was performed on rat brain mRNA using primers 
six-ire to the previously published A3 Ado receptor sequence 
[8] to amplify the entire coding region of the receptor (primers 
A and B, Fig, IA), The I kb product was cloned into pBlue~ 
script vector and subjected to sequence analysis. The sequence 
of this PCR product was found to differ by several nucleotides 
from that previously reported (Fig, 2). Subsequent restriction 
digests of additional clones showed that one clone exhibited 
slight;y less mobility than the expected A3 Ado receptor 
eDNA (Fig, I B), Sequence analysis of the eDNA showed 
that the slower 8el migration was due to a 51 bp insert in 
the ceding region of the rat A3 Ado receptor (Fig, 2). In 
addition, the insert was found to be in frame with the A3 
Ado receptor sequence, ncoding 17 amino acids in the second 
intracellular loop of the receptor (Fig. 3). This clone, desig- 
nated A3i, was the only one containing an insert among 12 
clones analyzed in the A3 Ado receptor eDNA pool, suggest- 
in8 a low abundance of its mRNA in brain tissue, 
The possibility that A3i might be a PCR-derived non-spe- 
cific product was first addressed by subjecting mRNA from 
rat spleen to RT-PCR with primers I and D (Fig. I A) in the 
presence and absence of reverse transcriptase. Only the re- 
verse-transcribed DNA yielded the expected 614 bp flag- 
ment, showing the insert in A3i to be contiguous with the 
A3 Ado receptor mRNA and ruling out the possibility of 
PCR artifact in the original A3i isolation (Fig. I C). In addi- 
tion, eDNA pools from rat brain and spleen tissues were used 
in PCR reactions using different primer pairs designed to de- 
tect both the A3 Ado receptor and A3i. As shown in Fig. 1 D, 
the primers C and F that span the A3 Ado receptor insert 
region, yielded PCR products of 537 bp and 588 bp corre- 
sponding to the A3 and A3i receptors respectively. While the 
yields of the PCR reactions were not quantitative, the relative 
intensities of the two products uggested that A3i likely repre- 
sents the minor species in the eDNA pools. PCR analysis of 
rat adipose DNA also demonstrated the presence of both A3 
and A3i Ado receptor mRNA (data not shown). 
In a separate series of PCR reactions, the full-length eDNA 
products of primers A and B were subjected to a second 
round of amplification with internal primers I and D (Fig. 
I D). The presence of A3i in the A/B eDNA pool was con- 
firmed by the 614 bp product in both brain and spleen. To- 
gether, these results trongly suggested that A3i is an authen- 
tic mRNA product that is likely present as a minor 
component of the A3 Ado receptor pool in these tissues. 
To characterize the genomic organization of the A3 Ado 
receptor locus, rat genomic DNA was subjected to PCR anal- 
ysis using primers E and F, spanning the insert regioll (Fig. 1). 
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A3i ATGAAAGCCAA~AATA~CACGACGAGTGC~TTGTGGTTGCAAATCACCTA~ATCAC~ATGGAGGCTGcCATT~~TGTA~AACATC4~rC~TCA~TCAAG 120 
A3 ATGAAAGCCAA~AATACCACGACGAGTC,CCT~q~=GTTGCAAATCA~CTACATCAcCA~CA~TGTA~CAT~'CTGGTCATCTGGGTGG~G 
I%226 A~.~AAGCCAACAATACCACGACGAGTGCCTTGTGGTTGCAAATCACCTACGTCACCATGGAGGCTGCCA~~TGT~CA~ATC~TCAAG 
A3i CTGAAC CGCACTCTGAGGACCACCACCTIL~A~TCGTCTC CTAGCACTGGCTGACATTGCTG~TC42TGGTCGTACCCTTGGCCATTGCCGTCAGCCTGGAGGTCCAGATG 240 
i%3 CTGAACCGCA~CCACCACCTrCTATTTCATCGTCTC C TAGCACTGGCIE~CATTGCTGTTGGGGTC-CTGGTCGTACC~CA~AGCCTGGAGGTCCAGATG 
I%226 ~TGAA~CGCA~TCTGAGGACCA~CA~TTCTATTTCATCGTCTCCCTAGCA~AGA~AT~C~TGTTGGGGTC42TGGTCATA~C~TrGGCCA~AGC~GGTCCAGATG 
A3i CACTTC TATGCCTGCCTTTTCATGTCCTGTGTC42T~TGGTC TTCACCCACGCTTCCATCATGTCCTI~ TGGCCATTC41-rGTAGACCGATACCTGCGAGTCAAGCTGACAGTCAGGTTG 360 
A3 CACT~TA~TGC~TGTCCTGTGTGCT~CTGGTCTTCA~CCACG~TTC~ATCA~`TCCTTGCTGGCCATTGCTGTAGA~CGATAC~GTCAAGCTGACAGTCAG .... 
R226 CACTTC TATGCC TGCCTI~FI~AT~T~CTGTGTGCTTCTGGTC1TcAC~CATGCTTCCATCAT~TCCTTGCTGGCCATTC.CTGTAGa~CGATAC~GTCAAGCTGAC~AG .... 
A3i TCATTTCTTGTTGTGAACTTA~CGTTTTC~TC~CCATTCAAA~AGATATAGAA~GGTTA~CACTCAAAGAAGAATATGGCTACTC~CTC~AGTGTCCTITC TGGTG 480 
A3 ............................................... ATATAGAACC43TTACCACTCAAAGAAGAATATGGCTACTC~CTCTC.42'PGC~2TAGTGTCCTI']~TGGTG 
R226 ............................................... ATATAGAACGGT~ACCACTCAAAGAAGAATATGGCTA~CTC~TAG~'TCCTITCTGGTG 
A3i GGACTGACCCCCAq~TTT~TAGAAAAGTGACC~TAGAGCTCTCTCAAAACAGCTCCA~CCTCTCATGCCACTTCCGTTC~ ~ A A ~ ~ ~  600 
A3 G~TGA~A~TAGAAAAGTC'A~CTTAGAGCTCTCTCAAAACAGCTC~AC~TCTCATGC~ACTTCCGTTCCGTC,GTCGGCTTGGATTACATGGTCTrCTTCAGC 
R226 GGACTGACCCCCA~TAGAAAAGTGAC CTTAGAGCTCTCTCAAAACAGCTCCACCC TCTCATGCCAC TTCCGTTTC~TGGTCGGC TEGGATTACATGG~AGC 
A3i TTCATCACCTGGATCCTCATCCCCC T~G~ATGTGCATCATCTATCTGGACATC TIL'TACATCATCCGAAACAAACTCAGTCAAAATCTGA~AGAGAGACC42G~A~ 720 
A3 TTCATCACCTGGATCCTCATC~TC.43~TCATGTGCATCATCTA~ATCTTCTACATCATC~GAAACAAACTCAGTCAAAA~~~~A~ 
R226 TTCATCACCTGGATCC TCATCCCCCTGGTT~"rCATGTGCATCATCTATC TGGACATC TTCTACATCATCCGAAACAAACTCAG~~~A~~CA~ 
A3i TAcGGTCGGGAGTTCAAGA~CGCTAAGTC~CTGTTTCTGGTTCTCTTCTTGTT~T'C~T~GTGCTGGCTGc~A~A~~~TA~~TAC~A~ 840 
A3 TACGGTCGGGAGTrCAAGACCGCTAAGTCCCTGTTTCTGGTTCTCTTCTI~TTTC~C TGTC, C TGGCTC, C CT i~G~CA~ATC~~C TAC~~TACCAG~ 
R~6 TAcGGTCGGGAGTTCA~GA~CGcTAAGTC~TGTTTCTGGTTcT~TrCT~TTT~TT~~~CA~ATC~~TA~~TACCAGAG 
A3i ATTC 'CAA~TGC~TGGGCATc~TTGTC~ATGCGAACTccATGATGAA~CTATTGTCTACG~C~T~G~~CcTA~A~A~A~ 960 
;%3 ATTGCAATGT~CCTGGGCATCc~TC~AT~CGAA~TCCATGATG~TATrGTCTACGC~TGCAAAAT~G~C~G~CcTAC~A~A~~ 
P~fi ATTGCAA'~Y]C~TGGGCATC~"~TC~AT~CG~A~TC~ATGATGAA~c~TA~G~TA~C~~T~G~~CCA~ ~ A ~ C ~ A ~ A ~  
• e 
A31 CTCTGTCAGACCTCGGAT|~TI~GGACTCGAACCTTGAACAGACTACTGAGTAG i 0 i4 
~.~ CTCTGTCAGACCTCGGATTCTTTGGACTCL%~ACCTTGAACAGACTACTGAGTAG 
R226 CTCTGTCAGACCTCGGATTCTTTC~3ACTCAAACCTTGAACAGACTAC~AGTAG 
Fig. 2. Nucleotide sequence alignment of the rat A3 Ado receptor coding regions. A3i and A3 are the sequences obtained from RT-PCR of 
brain mRNA. R226 is the previously published A3 sequence [8]. Dashed lines mark the position of the A3i insert region. Nucleotide differences 
are indicated by (e) below the specific nucleotide. Note that R226 has an insertion of A at position 863 and a deletion of T at position 884 to 
put the sequence back in frame. 
A 2.3 kb band was subsequently cloned and subjected to 
sequence analysis (Fig. 4). Results showed that the A3 locus 
contained a 1.7 kb intron located immediately upstream of the 
insert region. Furthermore, the insert was found to be contig- 
uous with the 3' exon immediately downstream. Analysis of 
the sequences surrounding the 51 bp insert identified consen- 
sus splice donor and acceptor sequences that enable the A3 
transcript to be alternatively spliced (Fig. 4). 
To analyze the distribution of the A3i receptor in various 
tissues, an oligonucleotide corresponding to the 51 bp inser! 
region of A3i eDNA was used as a hybridization probe in a 
rat maltiple tissue mRNA blot. However, no bands were de- 
tected (data not shown), indicating a low level of expression 
for this mRNA. In contrast, Northern blot analysis using the 
full-length A3i eDNA as probe (which hybridized to both A3 
and A3i) detected A3 transcripts primarily in three tissues 
(Fig. 5). Three transcripts of 2.0, 2.3 and 3.0 kb were present 
in the spleen. A single weak band at 3.0 kb was found in the 
lung and a highly expressed 1.8 kb transcript was present in 
the testis. Although the original clone was identified in the 
brain, Northern blot analysis was not sensitive nough to 
detect ranscripts in this tissue. The different band sizes de- 
tected in these tissues uggests that transcripts of the A3 gene 
are subject o extensive mRNA splicing. 
To further characterize the A3i receptor, cDNAs encoding 
both the rat A3 and A3i receptors were subcloned into the 
eukaryotic expression vector pcDNA3 and stably expressed in
CHO cells. Membrane fractions were prepared from the high- 
est expressing clones and analyzed for their ability to bind the 
A3-specific ligand I-ABA as previously described [11]. Unfor- 
tunately, specific binding was quite low (generally < 30%), 
and the total specific counts were insufficient to determine 
reliable binding affinities of various ligands (data not shown). 
Because of low specific binding in membrane preparations, a 
cAMP functional assay was used to test G protein coupling of 
the receptor in intact transfectants. As shown in Fig. 6, 
I-ABA modestly decreased forskolin-induced cAMP accumu- 
lation (P= 0.029; , = 4), although the efficacy was substan- 
tially less then that observed with the A3 Ado receptor. No 
suppression of cAMP was observed in CHO cells transfected 
with the neomycin resistance gene alone (data not shown). 
L) 
Fig. 3. The predicted amino acid sequence and transmembrane to- 
pology of the A3i Ado receptor. Putative N.glycosylation sites are 
indicated. The 17 amino acid insert in the second intraceilular do- 
main that is absent in the rat A3 receptor isshaded. 
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Fig, 4, Schematic of the rat A3 genomic region. (A) The splice junctions between the exons and the pattern of alternative splicing are indicated, 
The position of of the 51 bp insert is indicated by a solid bar, (B) The consensus sequences corresponding to the splice donor and acceptor 
sites are in capital letters and the insert sequence is underlined. Arrows denote the splice junctions. 
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Diverse physiological functions are modulated by the ac- 
tions of adenosine via a family of G-protein-coupled surface 
receptors [2]. To date four different classes of Ado receptors 
have been cloned from several species [1]. The A2a and A2b 
receptor subtypes are positively coupled to adenylate cyclase 
via stimulatory G proteins [4,5], whereas the AI and A3 sub- 
types couple to Gi proteins and suppress cAMP production 
[I,il]. Other signal transduction mechanisms have also been 
identified for various Ado receptors, including phospholipase 
C and nitric oxide for the A3 receptor [13,14] and potassium 
channels for the AI and A3 receptors [15,16]. The pharmacol- 
ogy of the A3 receptor is the least well characterized of the 
Ado receptor family, although recent data implicate it in car- 
diac preconditioning, mast cell degranulation, and suppres- 
sion of TNF-alpha production by macrophages [17-19]. 
During the process of cloning the A3 receptor eDNA from 
rat brain mRNA, we obtained a second larger clone that ap- 
peared to encode an alternatively spliced variant of the A3 
Ado receptor. The eDNA had complete homology to the se- 
quence of the rat A3 Ado receptor that was cloned simulta- 
neously by RT-PCR of rat brain mRNA except for the pres- 
ence of a 17 amino acid insert in the second intracellular loop. 
We also noted, however, that a number of nucleotide differ- 
ences existed between the sequences of these receptors and that 
reported for the original rat A3 Ado receptor [8]. The differ- 
ences are likely sec~uenctng errors in the original report and 
were also observed by Linden [17|. An extensive PCR analysis 
of mRlqA from various rat tissues as well as commercially 
obtained eDNA pools showed the presence of the A3i tran- 
script in all tissues tested, indicating that isolation of the A3i 
clone g~ not a PCR artifact. This was confirmed by the 
identification of 8enomic region encoding the insert region 
and its splicing sequences. Sequence analysis howed that the 
intron was immediately adjacent to the third trans-membrane, 
which is analogous to the organization of the A3 locus pre. 
viously reported in the human genome [20]. Furthermore, 
sint~e PCR analysis of the rat A3 gene using primers C and 
D (Fig. I) yielded a 2.3 kb fragment (data not shown), our 
results uggest that there is likely only a single intron within 
the rat gene coding region, as with the human homolog [20]. 
,~Ithough the eDNA for A3i was stably expressed in CHO 
cells, transfectants displayed weak binding characteristics 
compared to the A3 receptor (data not shown). Coupling to 
G proteins was observed when analyzed for the receptor's 
ability to inhibit forskolin-stimulated cAMP production, but 
suppression of cAMP was weak compared to the A3 Ado 
receptor. Poor receptor coupling can contribute to low specific 
binding, a phenomenon that has been previously described for 
G-coupled receptors [!,2]. 
Using PCR analysis on mRNA isolated from a variety of 
rat tissues, Zhou et al. [8] previously showed that the A3 Ado 
receptor, in contrast o the A! and A2 receptors, was only 
weakly detectable in the cortex and striatum, with the highest 
expression in the testis. Since no direct analysis of A3 tran- 
scripts had been previously reported, we analyzed mRNA 
from rat tissues by Northern blot analysis. The A3i Ado re- 
ceptor probe (which hybridized to both A3 and A3i) detected 
3 different sized transcripts in the spleen and a smaller, highly 
abundant ranscript in the testis. These studies support the 
notion that the rat A3 receptor gene is subject to extensive 
alternative splicing. 
Despite extensive PCR analysis, no variant A3 receptors 
were detected in human tissues (data not shown). This may 
not be surprising since, unlike the rat, the human and sheep 
I !!i i! i !ii i !ii!ii !i! iii l
1~4ctin 
Fig, 5. Northern blot hybridization of rat tissues with the A3i 
eDNA probe. Heart (H), brain (B), spleen (S), lung (L), liver (Li), 
muscle (M), kidney (K) and testis (T). The length of size markers 
(in kb) is indicated to the left. The blot was stripped of the rat A3i 
Ado receptor probe and rehybridized with a human 13-actin eDNA 
probe as control (below). Autoradiography was carried out with in- 
tensifying screens for 17 h (A3i) and 1 h (15-actin). 
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Fig. 6. Inhibition of cAMP accumulation by the A3 Ado receptor 
agonist I-ABA in forskolin-stimulated CHO cells expressing the A3 
or A3i Ado receptors. Cells were treated with forskolin (10 ltM) 
and I-ABA (! ttM) and cAMP measured using an immunoassay. 
Data are presented as the mean + S.E.M. of 4 separate xperiments 
and expressed as a percentage of forskolin-induced cAMP. 
*P = 0.008, ** P = 0.029 compared to forskolin alone. 
A3 receptor transcripts are of uniform ler, i~th in different is- 
sues [7,10]. Furthermore, the recent cloning of the human A3 
gone identified only a single intron, with a structural motif 
indicative of a gene that does not undergo alternative splicing 
[20]. This contrasts with extensive splicing that occurs in the 
human AI receptor [21]. 
The location of the insert in A3i suggests that this sequence 
might be invoYved in interactions with specific intracellular 
components that mediate receptor signaling. It also raises 
the possibility that the pharmacology of A3 observed in rat 
tissues might not have a corollary in humans ince a homo- 
logue was not identified. Moreover, the existence of variant 
A3 receptors in the rat may contribute to the observations by 
Fozard et al. on the role of A3 receptors in hemodynamic 
responses [22]. Given the widely divergent cDNA sequences, 
tissue distribution, and patterns of alternative splicing, the 
relevance of these non-human models to human A3 function 
should be viewed with caution. 
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